利拉鲁肽对NAFLD合并T2DM患者心血管代谢和左心室结构及功能的影响

宋白利; 付留俊; 常毅娜; 袁园; 姜宏卫; 彭慧芳

doi:10.6039/j.issn.1001-0408.2024.14.11

您当前的位置：

首页 >

文章列表页 >

利拉鲁肽对NAFLD合并T2DM患者心血管代谢和左心室结构及功能的影响

药物与临床 | 更新时间：2024-07-25

- 利拉鲁肽对NAFLD合并T2DM患者心血管代谢和左心室结构及功能的影响
- Effects of liraglutide on cardiovascular metabolism， left ventricular structure and function in NAFLD patients with T2DM
- 中国药房 2024年35卷第14期页码：1737-1742
- 作者机构：
  
  河南科技大学第一附属医院/河南科技大学临床医学院内分泌科，河南洛阳　471003
- 作者简介：
  
  副主任医师，硕士。研究方向：糖尿病及骨代谢。E-mail：bls3021@163.com
- 基金信息：
  
  河南省科技发展计划项目(222102310008)
- DOI：10.6039/j.issn.1001-0408.2024.14.11
  中图分类号： R58;R969.4
- 纸质出版日期：2024-07-30，
  
  收稿日期：2023-12-19，
  
  修回日期：2024-05-20，
- 稿件说明：
扫描看全文
宋白利,付留俊,常毅娜等.利拉鲁肽对NAFLD合并T2DM患者心血管代谢和左心室结构及功能的影响 ^Δ[J].中国药房,2024,35(14):1737-1742.

SONG Baili,FU Liujun,CHANG Yina,et al.Effects of liraglutide on cardiovascular metabolism， left ventricular structure and function in NAFLD patients with T2DM[J].ZHONGGUO YAOFANG,2024,35(14):1737-1742.
宋白利,付留俊,常毅娜等.利拉鲁肽对NAFLD合并T2DM患者心血管代谢和左心室结构及功能的影响 ^Δ[J].中国药房,2024,35(14):1737-1742. DOI： 10.6039/j.issn.1001-0408.2024.14.11.

SONG Baili,FU Liujun,CHANG Yina,et al.Effects of liraglutide on cardiovascular metabolism， left ventricular structure and function in NAFLD patients with T2DM[J].ZHONGGUO YAOFANG,2024,35(14):1737-1742. DOI： 10.6039/j.issn.1001-0408.2024.14.11.

摘要

目的

观察利拉鲁肽对非酒精性脂肪性肝病（NAFLD）合并2型糖尿病（T2DM）患者心血管代谢和左心室结构及功能的影响。

方法

回顾性选取2019年1月－2022年12月至我院内分泌科初次就诊的NAFLD合并T2DM患者351例，根据不同治疗方案分为对照组（196例）和观察组（155例）。对照组患者接受常规标准治疗方案，观察组在对照组基础上加用利拉鲁肽注射液0.6 mg/d，皮下注射，每天1次，7 d后调整至1.2 mg/d。两组患者均规律治疗超过12个月。采用倾向性匹配法对两组患者进行1∶1匹配后，比较其心血管代谢指标、心脏超声参数等，并分析左心室结构、功能参数与心血管代谢指标的相关性。

结果

倾向性匹配后，两组患者（各155例）治疗前的基线临床资料比较，差异均无统计学意义（

＞0.05）。治疗12个月后，两组患者的腰围、体重、体重指数（BMI）、收缩压（SBP）、空腹血糖（FBG）、糖化血红蛋白（HbA1c）、甘油三酯（TG）和观察组患者的舒张压（DBP）、总胆固醇（TC）、尿酸（UA）、左室心肌质量（LVM）均较同组治疗前显著降低（

＜0.05）；两组患者的高密度脂蛋白胆固醇（HDL-C）、估算肾小球滤过率（eGFR）、二尖瓣舒张早期血流峰值速度与二尖瓣舒张晚期血流峰值速度的比值（E/A比值），对照组患者的天冬氨酸转氨酶（AST），以及观察组患者的左室射血分数（LVEF）均较同组治疗前显著升高（

＜0.05），且观察组患者上述指标（TG、SBP除外）的改善普遍较对照组显著（

＜0.05）。两组患者治疗前后的左心室结构、功能参数（LVM、LVEF、E/A比值）与其腰围、体重、BMI、SBP、FBG、HbA1c有不同程度的关联，且BMI（观察组：

＝0.229，

＝0.004）和SBP（对照组：

＝0.240，

＝0.004；观察组：

＝0.226，

＝0.007）是患者LVM独立影响因素。

结论

在常规标准治疗方案基础上加用利拉鲁肽可有效控制NAFLD合并T2DM患者的血糖，降低其腰围、体重和血压，并改善其血脂紊乱，且对患者心脏结构和功能具有保护作用。

Abstract

OBJECTIVE

To observe the effects of liraglutide on cardiovascular metabolism， left ventricular structure and function of non-alcoholic fatty liver disease （NAFLD） patients with type 2 diabetes mellitus （T2DM）.

METHODS

Totally 351 NAFLD patients with T2DM were enrolled retrospectively， who visited the Department of Endocrinology in our hospital from January 2019 to December 2022. They were divided into control group （196 cases） and observation group （155 cases） according to different treatment regimens. The control group received conventional standard treatment， and the observation group was additionally given Liraglutide injection 0.6 mg/d subcutaneously once a day based on the control group， adjusted to 1.2 mg/d after 7 days. Both groups received regular treatment for more than 12 months. The propensity matching method was used to match the two groups of patients at a ratio of 1∶1. The cardiovascular metabolism indexes and cardiac ultrasound parameters were compared， and the correlation between left ventricular structure， function parameters and cardiovascular metabolism indexes was analyzed.

RESULTS

After propensity score matching， there was no significant difference in baseline clinical data between the two groups （each 155 cases） before treatment （

＞0.05）. After 12 months of treatment， the waist circumference， weight， body mass index （BMI）， systolic blood pressure （SBP）， fasting blood glucose （FBG）， glycosylated hemoglobin （HbA1c） and triglyceride （

TG） of both groups， as well as the diastolic blood pressure （DBP）， total cholesterol （TC）， uric acid （UA） and left ventricular mass （LVM） of the observation group， exhibited a significant decrease compared to pre-treatment levels （

＜0.05）. The high-density lipoprotein cholesterol （HDL-C）， estimated glomerular filtration rate （eGFR）， and E/A ratio in both groups， as well as the aspartate aminotransferase （AST） in the control group and the left ventricular ejection fraction （LVEF） in the observation group， were all significantly increased compared with before treatment in the same group （

＜0.05）. Moreover， the improvement of the above indicators （except for TG and SBP） in the observation group was generally more significant than those in the control group （

＜0.05）. The left ventricular structure and functional parameters （LVM， LVEF， E/A ratio） of the two groups before and after treatment had varying degrees of correlation with the patients’ waist circumference， body weight， BMI， SBP， FBG and HbA1c. Moreover， BMI （observation group：

＝0.229，

＝0.004） and SBP （control group：

＝0.240，

＝0.004； observation group：

＝0.226，

＝0.007） were independent influential factors for LVM of the patients.

CONCLUSIONS

Liraglutide combined with conventional standard treatment can effectively control blood glucose in NAFLD patients with T2DM， reduce waist circumference， body weight and blood pressure， improve blood lipid disorders， and protect their cardiac structure and function.

关键词

非酒精性脂肪性肝病2型糖尿病利拉鲁肽心血管疾病风险

Keywords

type 2 diabetes mellitusliraglutidecardiovascular risk

references

MARJOT T，MOOLLA A，COBBOLD J F，et al. Nonalcoholic fatty liver disease in adults：current concepts in etio-logy，outcomes，and management[J]. Endocr Rev，2020，41（1）：bnz009.

MUTHIAH M D，SANYAL A J. Burden of disease due to nonalcoholic fatty liver disease[J]. Gastroenterol Clin North Am，2020，49（1）：1-23.

HUANG D Q，DOWNES M，EVANS R M，et al. Shared mechanisms between cardiovascular disease and NAFLD[J]. Semin Liver Dis，2022，42（4）：455-464.

YOUNOSSI Z M，GOLABI P，AVILA L D，et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes：a systematic review and meta-analysis[J]. J Hepatol，2019，71（4）：793-801.

BRIL F，SNINSKY J J，BACA A M，et al. Hepatic steatosis and insulin resistance，but not steatohepatitis，promote atherogenic dyslipidemia in NAFLD[J]. J Clin Endocrinol Metab，2016，101（2）：644-652.

CAUSSY C，AUBIN A，LOOMBA R. The relationship between type 2 diabetes，NAFLD，and cardiovascular risk[J]. Curr Diab Rep，2021，21（5）：15.

CHAKHTOURA M，HABER R，GHEZZAWI M，et al. Pharmacotherapy of obesity：an update on the available medications and drugs under investigation[J]. EClinical-Medicine，2023，58：101882.

American Diabetes Association Professional Practice Committee. 6. glycemic targets：standards of medical care in diabetes：2022[J]. Diabetes Care，2022，45（Suppl. 1）：S83-S96.

KANE L T，FANG T L，GALETTA M S，et al. Propensity score matching：a statistical method[J]. Clin Spine Surg，2020，33（3）：120-122.

RHEE E J. Nonalcoholic fatty liver disease and diabetes：an epidemiological perspective[J]. Endocrinol Metab（Seoul），2019，34（3）：226-233.

RINELLA M E，NEUSCHWANDER-TETRI B A，SIDDIQUI M S，et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology，2023，77（5）：1797-1835.

HTIKE Z Z，ZACCARDI F，PAPAMARGARITIS D，et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes：a systematic review and mixed-treatment comparison analysis[J]. Diabetes Obes Metab，2017，19（4）：524-536.

LIN C H，SHAO L，ZHANG Y M，et al. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity[J]. Expert Opin Pharmacother，2020，21（3）：275-285.

FRIDMAN M，LUCAS M E，PAPROCKI Y，et al. Impact of weight change in adults with type 2 diabetes mellitus：a literature review and critical analysis[J]. Clinicoecon Outcomes Res，2020，12：555-566.

POPOVICIU M S，PĂDURARU L，YAHYA G，et al. Emerging role of GLP-1 agonists in obesity：a comprehensive review of randomised controlled trials[J]. Int J Mol Sci，2023，24（13）：10449.

WRONKA M，KRZEMIŃSKA J，MŁYNARSKA E，et al. New insights into the use of liraglutide-impact on cardiovascular risk and microvascular outcomes[J]. Biomedicines，2023，11（4）：1159.

SUN L L，ZHANG S J，CHEN M J，et al. Relationship between modulator recognition factor 2/AT-rich interaction domain 5B gene variations and type 2 diabetes mellitus or lipid metabolism in a northern Chinese population[J]. Chin Med J，2017，130（9）：1055-1061.

KELANY M E，HAKAMI T M，OMAR A H，et al. Combination of sitagliptin and insulin against type 2 diabetes mellitus with neuropathy in rats：neuroprotection and role of oxidative and inflammation stress[J]. Pharmacology，2016，98（5/6）：242-250.

PARK J，KIM G，KIM B S，et al. The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes：a nationwide cohort study[J]. Diabetes Res Clin Pract，2022，194：110191.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据